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Abstract
The Australian Group on Antimicrobial 
Resistance performs regular period-prevalence 
studies to monitor changes in antimicrobial 
resistance in selected enteric Gram-negative 
pathogens. The 2014 survey was the second 
year to focus on blood stream infections. During 
2014, 5,798 Enterobacteriaceae species iso-
lates were tested using commercial automated 
methods (Vitek 2, BioMérieux; Phoenix, BD) 
and results were analysed using the Clinical 
and Laboratory Standards Institute (CLSI) 
and European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) breakpoints 
(January 2015). Of the key resistances, non-
susceptibility to the third-generation cephalo-
sporin, ceftriaxone, was found in 9.0%/9.0% 
of Escherichia coli (CLSI/EUCAST criteria) and 
7.8%/7.8% of Klebsiella pneumoniae, and 
8.0%/8.0% K. oxytoca. Non-susceptibility rates 
to ciprofloxacin were 10.4%/11.6% for E. coli, 
5.0%/7.7% for K. pneumoniae, 0.4%/0.4% for 
K. oxytoca, and 3.5%/6.5% in Enterobacter cloa-
cae. Resistance rates to piperacillin-tazobactam 
were 3.2%/6.8%, 4.8%/7.2%, 11.1%/11.5%, and 
19.0%/24.7% for the same 4 species respec-
tively. Fourteen isolates were shown to harbour 
a carbapenemase gene, 7 blaIMP-4, 3 blaKPC-2, 
3 blaVIM-1, 1 blaNDM-4, and 1 blaOXA-181-lke .Commun 
Dis Intell 2016;40(2):E229–E235.
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Introduction
Emerging resistance in common pathogenic mem-
bers of the Enterobacteriaceae is a world-wide phe-
nomenon, and presents therapeutic problems for 
practitioners in both the community and in hospital 
practice. The Australian Group on Antimicrobial 
Resistance (AGAR) commenced surveillance of 
the key Gram-negative pathogens, Escherichia coli 
and Klebsiella species in 1992. Surveys have been 
conducted biennially until 2008 when annual 
surveys commenced, alternating between com-
munity– and hospital-onset infections.1 In 2004, 
another genus of Gram-negative pathogens in 
which resistance can be of clinical importance, 
Enterobacter species, was added. E. coli is the 
most common cause of community-onset urinary 
tract infection, while Klebsiella species are less 
common but are known to harbour important 
resistances. Enterobacter species are less common 
in the community, but of high importance due to 
intrinsic resistance to first-line antimicrobials in 
the community. Taken together, the three groups 
of species surveyed are considered to be valuable 
sentinels for multi-resistance and emerging resist-
ance in enteric Gram-negative bacilli. In 2013 
AGAR commenced the Enterobacteriaceae Sepsis 
Outcome Programme (EnSOP), which focused on 
the collection of resistance and some demographic 
data on all isolates prospectively from patients 
with bacteraemia. The 2014 survey was the second 
EnSOP survey.
Resistances of particular interest include resist-
ance to ß-lactams due to ß-lactamases, especially 
extended-spectrum ß-lactamases, which inactivate 
the third-generation cephalosporins that are nor-
mally considered reserve antimicrobials. Other 
resistances of interest are to agents important for 
treatment of these serious infections, such as gen-
tamicin; and resistance to reserve agents such as 
ciprofloxacin and meropenem.
The objectives of the 2014 surveillance program 
were to:
1. monitor resistance in Enterobacteriaceae iso-
lated from blood;
2. examine the extent of co-resistance and multi-
resistance; and
3. detect emerging resistance to newer last-line 
agents such as carbapenems.
Methods
Study design
From 1 January to 31 December 2014, 26 institu-
tions across Australia collected either all or up 
to 200 isolates from different patient episodes of 
bacteraemia.
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Species identification
Isolates were identified using the routine method 
for each institution; Vitek®, Phoenix™ Automated 
Microbiology System, or where available, mass 
spectrometry (MALDI-TOF).
Susceptibility testing
Testing was performed by 2 commercial semi-
automated methods, Vitek 2 (BioMérieux) or 
Phoenix (BD), which are calibrated to the ISO 
reference standard method of broth microdilu-
tion. Commercially available Vitek AST-N246, 
or Phoenix NMIC-203 cards were utilised by 
all participants throughout the survey period. 
The Clinical and Laboratory Standards Institute 
(CLSI) M1002 and European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) 
v5.03 breakpoints from January 2015 have been 
employed in the analysis. For analysis of cefazo-
lin, breakpoints of ≤ 4 for susceptible, and ≥ 8 
for resistant were applied due to the restricted 
minimum inhibitory concentration (MIC) range 
available on the commercial cards, recognising 
that the January 2015 breakpoint is actually sus-
ceptible ≤ 2 mg/L.
Molecular confirmation of resistances
E. coli and Klebsiella isolates with ceftazidime 
or ceftriaxone MIC > 1 mg/L, or cefoxitin MIC 
> 8 mg/L; Enterobacter spp. with cefepime MIC 
> 1 mg/L; all isolates with ciprofloxacin MIC 
> 0.25 mg/L; all isolates with meropenem MIC 
> 0.25 mg/L; and all isolates with amikacin MIC 
> 32 mg/L were referred to a central laboratory 
(SA Pathology) for molecular confirmation of 
resistance.
All referred isolates were screened for the pres-
ence of the blaTEM, and blaSHV genes using a 
real-time polymerase chain reaction (PCR) 
platform (LC-480) and published primers.4,5 A 
multiplex real-time TaqMan PCR was used to 
detect CTX-M-type genes.6 Strains were probed 
for plasmid-borne AmpC enzymes using the 
method described by Pérez-Pérez and Hanson,7 
and subjected to molecular tests for MBL (blaVIM, 
blaIMP, and blaNDM), blaKPC, and blaOXA-48-like genes 
using real-time PCR.8,9 Known plasmid mediated 
quinolone resistance mechanisms (Qnr, efflux 
(qepA, oqxAB), and aac(6’)-Ib-cr) were examined 
by PCR on all referred isolates with ciprofloxacin 
MIC > 0.25 mg/L using published methods.10,11 
All E. coli were examined for presence of the 
O25b-ST131 clone and its H30- and H30-Rx 
subclones.12–14
Results
The species isolated, and the numbers of each are 
listed in Table 1. Three genera, Escherichia spp., 
Klebsiella spp. and Enterobacter spp. contrib-
uted 87.6% of all isolates. Major resistances and 
non-susceptibilities for the top 6 ranked species 
are listed in Table 2. Non-susceptibility, (which 
includes both intermediately resistant and resistant 
strains), has been included for some agents because 
these figures provide information about important 
emerging acquired resistances. Multiple acquired 
resistances by species are shown in Table 3. Multi-
resistance was detected in 13.4% of E. coli isolates, 
9.7% of K. pneumoniae, and 12.1% of Ent. cloacae. 
A more detailed breakdown of resistances and non-
susceptibilities by state and territory is provided 
in the online report from the group (http://www.
agargroup.org/surveys).
Escherichia coli
Moderately high levels of resistance to ampicil-
lin (and therefore amoxycillin) were maintained 
(50.1%/51.9%, CLSI/EUCAST criteria), with 
lower rates for amoxycillin-clavulanate (12.7%/- 
intermediate, 8.2%/20.9% resistant). Non-
susceptibility to third-generation cephalosporins 
was low (ceftriaxone 9.0%/9.0%, ceftazidime 
Table 1: Species tested
Species Total %
Escherichia coli 3,493 60.2
Klebsiella pneumoniae 877 15.1
Enterobacter cloacae 343 5.9
Klebsiella oxytoca 226 3.9
Proteus mirabilis 187 3.2
Serratia marcescens 136 2.3
Enterobacter aerogenes 105 1.8
Salmonella species (non Typhi) 94 1.6
Morganella morganii 57 1.0
Citrobacter freundii 53 0.9
Citrobacter koseri 50 0.9
Salmonella Typhi/Paratyphi 26 0.4
Enterobacter asburiae 16 0.3
Raoultella ornithinolytica 15 0.3
Pantoea species 12 0.2
Pantoea agglomerans 12 0.2
Enterobacter species 11 0.2
Providencia stuartii 10 0.2
Other species (n=27) 75 1.3
Total 5,798
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4.4%/8.0%). Moderate levels of resistance were 
detected to cefazolin (20.5%/-) and trimethoprim 
(29.2%/29.4%). Ciprofloxacin non-susceptibility 
was found in 10.4%/11.6% of E. coli isolates. 
Resistance to ticarcillin-clavulanate (9.4%/19.3%), 
gentamicin (7.3%/7.5%), piperacillin-tazobactam 
(3.2%/6.8%), and cefepime (1.6%/2.9%) were low. 
Nine isolates had elevated meropenem MICs 
(≥ 0.5 mg/L). For the extended-spectrum ß-lacta-
mase (ESBL)-producing strains, ciprofloxacin and 
gentamicin resistance was found in 51.6%/51.6% 
and 33.8%/34.1% respectively.
In line with international trends among com-
munity strains of E. coli, most of the strains with 
ESBL genes harboured genes of the CTX-M 
type (222/272 = 82%). Over 60% of E. coli with 
CTX-M group 1 types were found to belong to 
sequence type 131 (O25b-ST131). ST131 accounted 
for 68% of E. coli ESBL phenotypes that were 
ciprofloxacin resistant (MIC > 1 mg/L), and only 
6% of ciprofloxacin susceptible ESBL phenotypes. 
Ninety-one per cent and 41% of O25b-ST131 were 
associated with the H30 and H30-Rx subclones, 
respectively, with their reported association with 
more antibiotic resistances and greater virulence 
potential.13
Klebsiella pneumoniae
K. pneumoniae showed slightly higher levels 
of resistance to piperacillin-tazobactam and 
ceftazidime compared with E. coli, but lower 
rates of resistance to amoxycillin-clavulanate, 
ticarcillin-clavulanate, cefazolin, ceftriaxone 
ciprofloxacin, gentamicin, and trimethoprim. 
Thirteen K. pneumoniae isolates had elevated 
meropenem MICs. ESBLs were present in 61 of 
69 (88%) presumptively ESBL-positive isolates of 
K. pneumoniae, 47 (77%) of which proved to be of 
the CTX-M type.
Enterobacter species
Acquired resistance was common to ticarcillin-
clavulanate (24.4%/29.7% and 26.7%/40.6%), 
piperacillin-tazobactam (19.0%/24.7% and 
23.1%/31.7%), ceftriaxone (27.3%/27.3% and 
37.5%/37.5%), ceftazidime (24.3%/24.6% and 
29.8%/33.7%) and trimethoprim (19.1%/19.1% 
and 1.9%/1.9%) for Ent. cloacae and Ent. aero-
genes, respectively. Cefepime, ciprofloxacin, and 
gentamicin resistance were all less than 10%. 
Seventeen of 45 Ent. cloacae tested for ESBL 
based on a suspicious phenotype, harboured 
ESBL-encoding genes. Eighteen Ent. cloacae 
strains had elevated meropenem MICs.
Carbapenemase resistance
Overall, 14 isolates (14 patients) in 9 institutions 
from 5 states or territories were found to harbour 
a carbapenemase gene. BlaIMP-4 was detected in 
E. cloacae (5) and K. pneumoniae (2); blaKPC-2 
was detected in 3 K. pneumoniae isolates from 
1 institution; blaVIM-1 
was detected in 2 K. pneu-
moniae; blaNDM-4 in 1 E. coli, and blaOXA-181-like in 
1 K. pneumoniae.
Discussion
AGAR has been tracking resistance in sentinel 
enteric Gram-negative bacteria since 1992. From 
2008, surveillance was segregated into hospital- 
versus community-onset infections. The last year 
of hospital-onset only surveillance was 2011.15 In 
2013, the first survey of antimicrobial resistance 
among Enterobacteriaceae isolates from bacterae-
mic patients throughout Australia was conducted 
using an approach similar to that conducted by 
the European EARS-Net program. The 2014 
survey was the second survey conducted of anti-
microbial resistance among Enterobacteriaceae 
isolates from bacteraemic patients throughout 
Australia.
CTX-M-producing E. coli and Klebsiella spe-
cies and gentamicin- and ciprofloxacin-resistant 
E. coli continued to be a problem in patients 
with bacteraemia. Of concern is the high propor-
tion of E. coli that belong to the ST131 H30-Rx 
subclone, and its reported association with 
more antibiotic resistance and greater virulence 
potential.13 Carbapenem resistance attributable to 
acquired carbapenemases are still uncommon in 
patients with bacteraemia in Australia, although 
5 different types (IMP, KPC, VIM, NDM and 
OXA-181-like) were detected from 9 of the par-
ticipating institutions. Compared with many 
other countries in our region, resistance rates in 
Australian Gram-negative bacteria are still rela-
tively low,16 but similar to those observed in 2014 
in many Western European countries.17
Multi-resistance is being increasingly observed, 
especially in E. coli and E. cloacae, both of which 
have multi-resistance rates (as defined by AGAR) 
above 10%. This is likely to drive more broad-spec-
trum antibiotic use, and increase the resistance 
selection pressure for important reserve classes, 
especially the carbapenemases.
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AGAR participants
Australian Capital Territory
Peter Collignon and Susan Bradbury, The 
Canberra Hospital
New South Wales
Thomas Gottlieb and Graham Robertson, 
Concord Hospital
John Ferguson and Jack (Ian) Winney, John 
Hunter Hospital
James Branley and Donna Barbaro, Nepean 
Hospital
George Kotsiou and Peter Huntington, Royal 
North Shore Hospital
David Mitchell and Lee Thomas, Westmead 
Hospital
Northern Territory
Rob Baird and Jann Hennessy, Royal Darwin 
Hospital
Queensland
Enzo Binotto and Bronwyn Thomsett, Pathology 
Queensland Cairns Base Hospital
Graeme Nimmo and Narelle George, Pathology 
Queensland Central Laboratory
Petra Derrington and Sharon Dal-Cin, Pathology 
Queensland Gold Coast Hospital
Robert Horvath, Pathology Queensland Prince 
Charles Hospital
Naomi Runnegar and Joel Douglas, Pathology 
Queensland Princess Alexandra Hospital
Jenny Robson and Georgia Peachey, Sullivan 
Nicolaides Pathology
South Australia
Kelly Papanoum and Nicholas Wells, SA Pathology 
(Flinders Medical Centre)
Morgyn Warner and Kija Smith, SA Pathology 
(Royal Adelaide Hospital)
John Turnidge and Jan Bell, SA Pathology 
(Women’s and Children’s Hospital)
Tasmania
Louise Cooley and Rob Peterson, Royal Hobart 
Hospital
Victoria
Denis Spelman, Amanda Dennison and 
Christopher Lee, Alfred Hospital
Benjamin Howden and Peter Ward, Austin 
Hospital
Tony Korman and Despina Kotsanas, Southern 
Health, Monash Medical Centre
Andrew Daley and Gena Gonis, Royal Women’s 
Hospital
Mary Jo Waters and Linda Joyce, St Vincent’s 
Hospital
Western Australia
David McGechie and Rebecca Wake, PathWest 
Laboratory Medicine - WA, Fremantle Hospital
Ronan Murray and Barbara Henderson, PathWest 
Laboratory Medicine – WA, Queen Elizabeth II 
Hospital
Owen Robinson, Denise Daley and Geoffrey 
Coombs, PathWest Laboratory Medicine – WA, 
Royal Perth Hospital
Sudha Pottumarthy-Boddu and Fay Kappler, 
St John of God Pathology
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